As an immunotherapy adjuvant, IPA sustains stem-like properties of CD8+ T cells by promoting H3K27 acetylation at the Tcf7 super-enhancer, thereby enhancing responsiveness to anti-PD-1 therapy across multiple cancer models [107]. The gene discussed is PDCD1; the disease is cancer.